Yunsoo Kim

Array ( [id] => 18159214 [patent_doc_number] => 20230025806 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-01-26 [patent_title] => STABLE COMPOSITIONS OF FC MULTIMERS [patent_app_type] => utility [patent_app_number] => 17/782404 [patent_app_country] => US [patent_app_date] => 2020-12-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 27112 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17782404 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18178539 [patent_doc_number] => 20230039268 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-02-09 [patent_title] => ANTI-PD-L1 ANTIBODY FORMULATIONS [patent_app_type] => utility [patent_app_number] => 17/783229 [patent_app_country] => US [patent_app_date] => 2020-12-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25583 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -53 [patent_words_short_claim] => 155 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17783229 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18193640 [patent_doc_number] => 20230047159 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-02-16 [patent_title] => REGULATORY T CELL (TREG) COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASE [patent_app_type] => utility [patent_app_number] => 17/292423 [patent_app_country] => US [patent_app_date] => 2020-12-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 83778 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -121 [patent_words_short_claim] => 43 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17292423 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16711902 [patent_doc_number] => 20210079049 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-03-18 [patent_title] => Engineered Biofilms [patent_app_type] => utility [patent_app_number] => 17/106105 [patent_app_country] => US [patent_app_date] => 2020-11-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11737 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 24 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17106105 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17022317 [patent_doc_number] => 20210246188 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-08-12 [patent_title] => COMPOSITIONS AND METHODS FOR PRODUCING A COMPOSITION [patent_app_type] => utility [patent_app_number] => 17/105358 [patent_app_country] => US [patent_app_date] => 2020-11-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 212908 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17105358 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16718645 [patent_doc_number] => 20210085792 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-03-25 [patent_title] => Liquid Protein Formulations Containing Viscosity-Lowering Agents [patent_app_type] => utility [patent_app_number] => 17/101063 [patent_app_country] => US [patent_app_date] => 2020-11-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 33295 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 20 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17101063 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16977655 [patent_doc_number] => 20210221892 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-07-22 [patent_title] => ANTI-PDL1 ANTIBODY FORMULATIONS [patent_app_type] => utility [patent_app_number] => 17/101966 [patent_app_country] => US [patent_app_date] => 2020-11-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 37434 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17101966 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18093141 [patent_doc_number] => 20220411482 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-12-29 [patent_title] => STABLE FORMULATIONS OF SILK-DERIVED PROTEIN [patent_app_type] => utility [patent_app_number] => 17/785392 [patent_app_country] => US [patent_app_date] => 2020-11-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 27962 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17785392 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18065543 [patent_doc_number] => 20220396630 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-12-15 [patent_title] => TYPE I INTERFERON INHIBITION IN SYSTEMIC LUPUS ERYTHEMATOSUS [patent_app_type] => utility [patent_app_number] => 17/755801 [patent_app_country] => US [patent_app_date] => 2020-11-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 28170 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -33 [patent_words_short_claim] => 14 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17755801 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18169006 [patent_doc_number] => 20230035617 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-02-02 [patent_title] => STABLE AQUEOUS ANTI-TFPI ANTIBODY FORMULATION [patent_app_type] => utility [patent_app_number] => 17/755573 [patent_app_country] => US [patent_app_date] => 2020-11-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25940 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -27 [patent_words_short_claim] => 72 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17755573 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18169006 [patent_doc_number] => 20230035617 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-02-02 [patent_title] => STABLE AQUEOUS ANTI-TFPI ANTIBODY FORMULATION [patent_app_type] => utility [patent_app_number] => 17/755573 [patent_app_country] => US [patent_app_date] => 2020-11-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25940 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -27 [patent_words_short_claim] => 72 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17755573 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19225472 [patent_doc_number] => 12005102 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-06-11 [patent_title] => Anti-abeta therapeutic vaccines [patent_app_type] => utility [patent_app_number] => 17/091553 [patent_app_country] => US [patent_app_date] => 2020-11-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 9 [patent_no_of_words] => 12379 [patent_no_of_claims] => 23 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 68 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17091553 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17109928 [patent_doc_number] => 20210290525 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-09-23 [patent_title] => FORMULATIONS OF ANTIBODY [patent_app_type] => utility [patent_app_number] => 17/085316 [patent_app_country] => US [patent_app_date] => 2020-10-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4022 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17085316 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19179951 [patent_doc_number] => 11986526 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-05-21 [patent_title] => Liquid protein formulations containing 4-ethyl-4-methylmorpholinium methylcarbonate (EMMC) [patent_app_type] => utility [patent_app_number] => 17/073618 [patent_app_country] => US [patent_app_date] => 2020-10-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25911 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 84 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17073618 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18724381 [patent_doc_number] => 20230338526 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-10-26 [patent_title] => ANTI-CD20 ANTIBODY FORMULATION AND USE OF ANTI-CD20 ANTIBODY FOR TREATMENT OF CD20 POSITIVE DISEASES [patent_app_type] => utility [patent_app_number] => 17/767990 [patent_app_country] => US [patent_app_date] => 2020-10-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25037 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -43 [patent_words_short_claim] => 81 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17767990 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18777874 [patent_doc_number] => 11819550 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-11-21 [patent_title] => Liquid protein formulations containing cyclic adenosine monophosphate (cAMP) or adenosine triphosphate (ATP) [patent_app_type] => utility [patent_app_number] => 17/067058 [patent_app_country] => US [patent_app_date] => 2020-10-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 25604 [patent_no_of_claims] => 28 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 123 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17067058 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16727903 [patent_doc_number] => 20210095050 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-04-01 [patent_title] => PROCESS FOR CONCENTRATION OF ANTIBODIES AND THERAPEUTIC PRODUCTS THEREOF [patent_app_type] => utility [patent_app_number] => 17/017465 [patent_app_country] => US [patent_app_date] => 2020-09-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16100 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17017465 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16776620 [patent_doc_number] => 20210113697 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-04-22 [patent_title] => EXCIPIENT COMPOUNDS FOR PROTEIN FORMULATIONS [patent_app_type] => utility [patent_app_number] => 17/011014 [patent_app_country] => US [patent_app_date] => 2020-09-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 42985 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -29 [patent_words_short_claim] => 41 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17011014 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16555806 [patent_doc_number] => 20210000954 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-01-07 [patent_title] => STABLE ANTI-PD-1 ANTIBODY PHARMACEUTICAL PREPARATION AND APPLICATION THEREOF IN MEDICINE [patent_app_type] => utility [patent_app_number] => 16/948077 [patent_app_country] => US [patent_app_date] => 2020-09-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6411 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 31 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16948077 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16657414 [patent_doc_number] => 20210054050 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-02-25 [patent_title] => FORMULATION OPTIMIZATION FOR BISPECIFIC ANTIBODIES [patent_app_type] => utility [patent_app_number] => 16/998391 [patent_app_country] => US [patent_app_date] => 2020-08-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8637 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -35 [patent_words_short_claim] => 70 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16998391 [rel_patent_id] =>[rel_patent_doc_number] =>)